Health Canada approves sales of Relora

Health Canada approves sales of Relora

Relora contains Magnolia officinalis and Phellodendron amurense bark extracts to aid in stress management.

Health Canada has issued NPN 505349 for Relora, enabling the all-natural dietary supplement to be sold throughout Canada. Health Canada is the country’s federal department responsible for “helping Canadians maintain and improve their health” and rewarding these product licenses, required by all natural health products sold in Canada. Health Canada’s review process is highly selective to ensure the quality of products sold throughout the country.

Relora, sold in the U.S. since 2000 (US Patent No. 6,582,735), helps with stress and promotes weight management by quieting the hypothalamic-pituitary-adrenal axis without causing drowsiness. Relora’s ingredients, a blend of Magnolia officinalis and Phellodendron amurense bark extracts, have been used in Traditional Chinese Medicine for thousands of years.

Relora is the leading supplement in its category in the U.S. It is a powder available for use in capsule form for oral administration. Relora is a product of Next Pharmaceuticals. Companies located in Canada can purchase Relora through Next Pharmaceuticals’ exclusive distributor, EnZed Nutricorp.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.